Cost-Effectiveness Analysis Of Ceritinib And Alectinib Versus Crizotinib In The Treatment Of Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer

Cancer Management and Research ◽

10.2147/cmar.s223441 ◽

2019 ◽

Vol Volume 11 ◽

pp. 9195-9202 ◽

Cited By ~ 3

Author(s):

Maobai Liu ◽

Longfeng Zhang ◽

Qishu Huang ◽

Na Li ◽

Bin Zheng ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Anaplastic Lymphoma Kinase ◽

Cost Effectiveness Analysis ◽

Small Cell ◽

Small Cell Lung ◽

Anaplastic Lymphoma ◽

Effectiveness Analysis

Download Full-text

Cost-Effectiveness Analysis of Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer in Portugal

Value in Health ◽

10.1016/j.jval.2017.08.206 ◽

2017 ◽

Vol 20 (9) ◽

pp. A434

Author(s):

P Saramago ◽

M Ines ◽

F Saraiva

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Anaplastic Lymphoma Kinase ◽

Cost Effectiveness Analysis ◽

Small Cell ◽

Small Cell Lung ◽

Anaplastic Lymphoma ◽

Effectiveness Analysis

Download Full-text

PCN140 - COST-EFFECTIVENESS ANALYSIS OF ALECTINIB VS CRIZOTINIB IN FIRST LINE ANAPLASTIC LYMPHOMA KINASE POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER IN PORTUGAL

Value in Health ◽

10.1016/j.jval.2018.09.223 ◽

2018 ◽

Vol 21 ◽

pp. S38

Author(s):

V. Soares ◽

P. Orfanos ◽

C. Pereira

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Anaplastic Lymphoma Kinase ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Anaplastic Lymphoma ◽

Effectiveness Analysis

Download Full-text

Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada

PharmacoEconomics ◽

10.1007/s40273-021-01022-9 ◽

2021 ◽

Author(s):

Yong-Jin Kim ◽

Mark Oremus ◽

Helen H. Chen ◽

Thomas McFarlane ◽

Danielle Fearon ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Egfr Mutation ◽

Cost Effectiveness Analysis ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Effectiveness Analysis

Download Full-text

Cost-effectiveness Analysis of Robotic-assisted Lobectomy for Non-small Cell Lung Cancer

The Annals of Thoracic Surgery ◽

10.1016/j.athoracsur.2021.06.090 ◽

2021 ◽

Author(s):

Brendan T. Heiden ◽

Joshua D. Mitchell ◽

Eric Rome ◽

Varun Puri ◽

Bryan F. Meyers ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Cost Effectiveness Analysis ◽

Small Cell ◽

Small Cell Lung ◽

Robotic Assisted ◽

Effectiveness Analysis

Download Full-text

PCN107 Cost-Effectiveness Analysis of Lorlatinib in Patients Previously Treated with Anaplastic Lymphoma Kinase Inhibitors for NON-SMALL CELL LUNG Cancer in Greece

Value in Health ◽

10.1016/j.jval.2020.08.244 ◽

2020 ◽

Vol 23 ◽

pp. S442

Author(s):

G. Gourzoulidis ◽

O. Zisimopoulou ◽

N. Boubouchairopoulou ◽

C. Michailidi ◽

C. Almond ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Anaplastic Lymphoma Kinase ◽

Kinase Inhibitors ◽

Small Cell ◽

Small Cell Lung ◽

Anaplastic Lymphoma ◽

Effectiveness Analysis ◽

Previously Treated

Download Full-text

A Trial-Based Cost-Effectiveness Analysis of Bevacizumab and Chemotherapy Versus Chemotherapy Alone for Advanced Nonsquamous Non–Small-Cell Lung Cancer in China

Value in Health Regional Issues ◽

10.1016/j.vhri.2018.05.001 ◽

2019 ◽

Vol 18 ◽

pp. 1-7 ◽

Cited By ~ 1

Author(s):

Xinyan Li ◽

Weichen Li ◽

Lingping Hou

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Cost Effectiveness Analysis ◽

Small Cell ◽

Small Cell Lung ◽

Effectiveness Analysis

Download Full-text

Durvalumab consolidation therapy in patients with stage III non-small cell lung cancer after concurrent chemoradiation: a China-based cost-effectiveness analysis

Expert Review of Pharmacoeconomics & Outcomes Research ◽

10.1080/14737167.2022.1993062 ◽

2021 ◽

Author(s):

Xuan Chen ◽

Zhiguang Yang ◽

Guiyuan Xiang ◽

Lingna Gu ◽

Ziheng Qi ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Cost Effectiveness Analysis ◽

Small Cell ◽

Concurrent Chemoradiation ◽

Consolidation Therapy ◽

Small Cell Lung ◽

Effectiveness Analysis

Download Full-text

Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis

Clinical Drug Investigation ◽

10.1007/s40261-019-00869-3 ◽

2019 ◽

Vol 40 (2) ◽

pp. 129-137 ◽

Cited By ~ 3

Author(s):

Qiao Liu ◽

Xia Luo ◽

Liubao Peng ◽

Lidan Yi ◽

Xiaomin Wan ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Cost Effectiveness Analysis ◽

Small Cell ◽

Small Cell Lung ◽

Effectiveness Analysis ◽

Previously Treated

Download Full-text

Journal of Aging & Pharmacotherapy ◽

10.3109/j397v13n02_09 ◽

2006 ◽

Vol 13 (2) ◽

pp. 109-126 ◽

Cited By ~ 2

Author(s):

Daniel R. Touchette ◽

J. G. Stevenson ◽

Gail Jensen

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Cost Effectiveness Analysis ◽

Small Cell ◽

Small Cell Lung ◽

Effectiveness Analysis

Download Full-text

Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China

Journal of Medical Economics ◽

10.1080/13696998.2019.1570221 ◽

2019 ◽

Vol 22 (4) ◽

pp. 344-349 ◽

Cited By ~ 11

Author(s):

Weiting Liao ◽

Jiaxing Huang ◽

David Hutton ◽

Qiu Li

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Cost Effectiveness Analysis ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Effectiveness Analysis

Download Full-text

Cost-Effectiveness Analysis Of Ceritinib And Alectinib Versus Crizotinib In The Treatment Of Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer

Cost-Effectiveness Analysis of Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer in Portugal

PCN140 - COST-EFFECTIVENESS ANALYSIS OF ALECTINIB VS CRIZOTINIB IN FIRST LINE ANAPLASTIC LYMPHOMA KINASE POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER IN PORTUGAL

Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada

Cost-effectiveness Analysis of Robotic-assisted Lobectomy for Non-small Cell Lung Cancer

PCN107 Cost-Effectiveness Analysis of Lorlatinib in Patients Previously Treated with Anaplastic Lymphoma Kinase Inhibitors for NON-SMALL CELL LUNG Cancer in Greece

A Trial-Based Cost-Effectiveness Analysis of Bevacizumab and Chemotherapy Versus Chemotherapy Alone for Advanced Nonsquamous Non–Small-Cell Lung Cancer in China

Durvalumab consolidation therapy in patients with stage III non-small cell lung cancer after concurrent chemoradiation: a China-based cost-effectiveness analysis

Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis

Cost-Effectiveness Analysis of Amifostine (Ethyol©) in Patients with Non-Small Cell Lung Cancer

Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China

Export Citation Format